MedPath

Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly

Not Applicable
Recruiting
Conditions
Hypoxia
Exercise
Cerebral Hypoxia
Brain Diseases
Aging
Cognitive Decline
Healthy Aging
Registration Number
NCT05048680
Lead Sponsor
University Hospital, Grenoble
Brief Summary

In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
64
Inclusion Criteria
  • 60 to 80 years of age;
  • Being physically inactive (less than 150 min/week of moderate to intense physical activity);
  • No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;
  • Health coverage;
  • Being able to provide written fully informed consent.
Exclusion Criteria
  • Body-mass index >30 kg/m2;
  • Smoking (> cigarettes/day);
  • Alcohol use (> 10g/day);
  • Mental disorder or history of mental disorder;
  • Beta-blockade treatment;
  • Inability or refusal to provide informed consent;
  • No health coverage
  • People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;
  • People deprived of freedom by judicial or administrative decision;
  • People subject to legal protection, who cannot be included in clinical trials.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Middle cerebral artery flow velocityBefore intervention; right after intervention; 2 months after intervention

Changes in middle cerebral artery flow velocity in response to hypercapnia (5% CO2)

Secondary Outcome Measures
NameTimeMethod
Cognitive functionBefore intervention; right after intervention; 2 months after intervention

Cognitive function assessed by the Montreal Cognitive Assessment questionnaire

Health-related quality of lifeBefore intervention; right after intervention; 2 months after intervention

Health-related quality of life assessed by the SF-36 questionnaire

Blood pressureBefore intervention; right after intervention; 2 months after intervention

24h (systolic, diastolic and mean) blood pressure assessment

SleepBefore intervention; right after intervention; 2 months after intervention

Sleep features assessed by polygraphy

Peak oxygen uptakeBefore intervention; right after intervention; 2 months after intervention

Peak oxygen uptake during a cardiopulmonary exercise test

Flow-mediated dilationBefore intervention; right after intervention; 2 months after intervention

Flow-mediated dilation in response to ischemia-reperfusion of the brachial artery

Trial Locations

Locations (1)

CHU Grenoble Alpes

🇫🇷

La Tronche, Auvergne Rhône-Alpes, France

CHU Grenoble Alpes
🇫🇷La Tronche, Auvergne Rhône-Alpes, France
Stéphane Doutreleau, MD, PhD
Contact
+33476767773
sdoutreleau@chu-grenoble.fr
Samuel Vergès, PhD
Contact
+33476766860
sverges@chu-grenoble.fr

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.